Pratol
Based on 1 Customer Validation
Pratol (7-Hydroxy-4'-methoxyflavone) is an NF-κB inhibitor. Pratol also inhibits NO, PGE2, TNF-α, IL-1β, and IL-6 production. Pratol increases the phosphorylation of p38 MAPK, JNK, and ERK, decreases AKT phosphorylation, and upregulates MITF, tyrosinase, TRP-1, and TRP-2 through a PKA-dependent signaling pathway. Pratol reduces iNOS and COX-2 protein expression, inhibits p65 phosphorylation, and protects IκBα from degradation, thereby inhibiting NF-κB nuclear translocation. Pratol can be used in research on hypopigmentary disorders, inflammatory diseases, cervical cancer, and colon cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.16%
- CAS. Nr.: 487-24-1
- Formel: C16H12O4
- Molecular Weight:268.26
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
|
NF-κB |
IL-1β |
TNF-α |
IL-6 |
p38 MAPK |
JNK |
ERK |
Akt |
PKA |
MITF |
p65 |
TRP-1 |
TRP-2 |
IκBα |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
25.73 μg/mL
|
Cytotoxicity against human HeLa cervical cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against human HeLa cervical cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
1.4978148 |
| WiDr | IC50 |
83.75 μg/mL
|
Cytotoxicity against human WiDr colon cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against human WiDr colon cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
1.4978148 |
In Vitro
Pratol (6.25-50 μM; 48 h) significantly increased melanin content in B16F10 mouse melanoma cells in a dose-dependent manner, with no cytotoxicity at concentrations up to 50 μM[1].
Pratol (6.25-50 μM; 72 h) increases tyrosinase activity in B16F10 mouse melanoma cells in a dose-dependent manner[1].
Pratol (6.25-50 μM; 48 h (tyrosinase, TRP-1, TRP-2); 24 h (MITF dose-response); 22-24 h (MITF time-course)) increases the protein expression of tyrosinase, TRP-1, TRP-2, and MITF in B16F10 mouse melanoma cells[1].
Pratol (6.25-50 μM; 4 h) inhibits AKT phosphorylation in B16F10 mouse melanoma cells in a dose-dependent manner[1].
Pratol (6.25-50 μM; 4 h) activates the MAPK pathway by increasing the phosphorylation of p38, ERK, and JNK in B16F10 mouse melanoma cells[1].
Pratol increases tyrosinase activity and melanogenesis gene expression in B16F10 mouse melanoma cells through a PKA-dependent signaling pathway[1].
Pratol (7-Hydroxy-4'-methoxyflavone) (24 h) exhibited active cytotoxic effects against HeLa cervical cancer cells with an IC50 of 25.73 µg/mL, and showed considerable activity against WiDr colon cancer cells with an IC50 of 83.75 µg/mL[3].
Pratol (6.25-50 μM (Pratol); 10 μM (inhibitors))-induced tyrosinase upregulation is associated with the activation of p38 and JNK, but not the ERK pathway, in B16F10 mouse melanoma cells[1].
Pratol (25-100 μM; 24 h) inhibits NO production in LPS-stimulated RAW 264.7 cells, with at least 45% inhibition of production at 100 μM[2].
Pratol (25-100 μM; 24 h) concentration-dependently inhibited PGE2 production in LPS-stimulated RAW 264.7 cells, with at least 85% inhibition of production at 100 μM[2].
Pratol (25-100 μM; 24 h) concentration-dependently inhibited the production of TNF-α, IL-1β, and IL-6 in LPS-stimulated RAW 264.7 cells[2].
Pratol (25-100 μM; 24 h) downregulates iNOS and COX-2 protein expression in LPS-stimulated RAW 264.7 cells[2].
Pratol (25-100 μM; 30 min) protects IκBα from degradation in LPS-stimulated RAW 264.7 cells[2].
Pratol (25-100 μM; 30 min) inhibits p65 phosphorylation in LPS-stimulated RAW 264.7 cells, thereby inhibiting the NF-κB signaling pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B16F10 mouse melanoma cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM; 50 μM
-
Incubation Time:48 h
-
Result:Increased melanin content to 99.2%, 108.9%, 176.2%, and 208.7% at 6.25, 12.5, 25, and 50 μM, respectively.
Maintained cell viability at 101.0%, 99.2%, 92.1%, and 88.4% at 6.25, 12.5, 25, and 50 μM, respectively.
-
Cell Line:B16F10 mouse melanoma cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM; 50 μM
-
Incubation Time:48 h (tyrosinase, TRP-1, TRP-2); 24 h (MITF dose-response); 22-24 h (MITF time-course)
-
Result:Significantly increased the expression of tyrosinase, TRP-1, and TRP-2.
Increased MITF expression in a time- and concentration-dependent manner, reaching a maximum level after 24 h of treatment.
-
Cell Line:B16F10 mouse melanoma cells
-
Concentration:6.25 μM; 12.5 μM; 25 μM; 50 μM
-
Incubation Time:4 h
-
Result:Reduced AKT phosphorylation in a dose-dependent manner, with significant reduction observed at 50 μM.\nSignificantly increased the phosphorylation of p38 MAPK, ERK, and JNK in a dose-dependent manner.
-
Cell Line:RAW 264.7 macrophages
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Decreased PGE2 production in a concentration-dependent manner.
Inhibited PGE2 production by at least 85% at 100 μM.\nInhibited the expression of TNF-α, IL-1β, and IL-6 in a concentration-dependent manner relative to LPS alone.
-
Cell Line:RAW 264.7 macrophages
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Significantly decreased protein levels of iNOS and COX-2 compared to LPS alone.
-
Cell Line:RAW 264.7 macrophages
-
Concentration:25, 50, 100 μM
-
Incubation Time:30 min
-
Result:Significantly upregulated IκBα expression compared to LPS alone.\nSignificantly decreased p-p65 levels compared to LPS alone.
Chemical Information
-
CAS. Nr. 487-24-1
-
Appearance Solid
-
Molecular Weight 268.26
-
Formel C16H12O4
-
Color White to yellow
-
SMILES
O=C1C=C(C2=CC=C(OC)C=C2)OC3=CC(O)=CC=C13
-
Synonyms
7-Hydroxy-4'-methoxyflavone
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 75 mg/mL (279.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
Reinheit & Dokumentation
-
Data Sheet (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7277 mL | 18.6386 mL | 37.2773 mL | 93.1932 mL |
| 5 mM | 0.7455 mL | 3.7277 mL | 7.4555 mL | 18.6386 mL | |
| 10 mM | 0.3728 mL | 1.8639 mL | 3.7277 mL | 9.3193 mL | |
| 15 mM | 0.2485 mL | 1.2426 mL | 2.4852 mL | 6.2129 mL | |
| 20 mM | 0.1864 mL | 0.9319 mL | 1.8639 mL | 4.6597 mL | |
| 25 mM | 0.1491 mL | 0.7455 mL | 1.4911 mL | 3.7277 mL | |
| 30 mM | 0.1243 mL | 0.6213 mL | 1.2426 mL | 3.1064 mL | |
| 40 mM | 0.0932 mL | 0.4660 mL | 0.9319 mL | 2.3298 mL | |
| 50 mM | 0.0746 mL | 0.3728 mL | 0.7455 mL | 1.8639 mL | |
| 60 mM | 0.0621 mL | 0.3106 mL | 0.6213 mL | 1.5532 mL | |
| 80 mM | 0.0466 mL | 0.2330 mL | 0.4660 mL | 1.1649 mL | |
| 100 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.9319 mL |
Keywords
- Pratol
- 487-24-1
- 7-Hydroxy-4'-methoxyflavone
- NF-κB
- PGE synthase
- TNF Receptor
- Interleukin Related
- p38 MAPK
- JNK
- ERK
- Akt
- PKA
- Microphthalmia Associated Transcription Factor (MITF)
- TRP Channel
- NO Synthase
- COX
- IKK
- RAW 264.7 cells
- B16F10 mouse melanoma cells
- MITF
- HeLa cervical cancer cells
- melanogenesis inducer
- WiDr colon cancer cells
- Inhibitor
- inhibitor
- inhibit